EMEA advice on rosiglitazone

The prescribing information for the type-2 diabetes drug rosiglitazone should be updated to include safety warnings, the European Medicines Agency (EMEA) has announced.

The benefits of using rosiglitazone were found to outweigh the risks, according to the EMEA.

However, it recommends that the prescribing information should be updated to include a warning that, in patients with ischaemic heart disease, rosiglitazone should only be used after careful evaluation of risk.

Additionally, the combination of rosiglitazone and insulin should only be used in exceptional cases and under close supervision.

The changes will be introduced in forthcoming regulatory procedures for rosiglitazone-containing medicines. But no changes will be made to the prescribing information for medicines containing pioglitazone.

Comment below and tell us what you think 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

Hospital entrance

NHS England issues warning over norovirus and rising winter pressures

Almost three times as many people were in hospital with norovirus last week compared...

BMA Northern Ireland GP committee chair Dr Alan Stout

Northern Ireland GPs face deepest-ever crisis as practices hand back contracts

Northern Ireland's GP leader has warned that general practice in the region is facing...

GP consulting room

GP appointments hit record high of over 34m in October

GP practices delivered a record 34.3m appointments in October this year excluding...

GP consultation

New contract that enforces continuity would make GPs and patients safer, says watchdog

A new GP contract that makes continuity of care an 'essential requirement' for practices...

GP receptionist on the phone

Some practices to receive funding to upgrade digital phone systems

GP practices whose digital phone systems do not meet new NHS England standards will...

Woman using mobile phone

Safety issues with remote GP consultations 'extremely rare', study shows

Safety incidents are 'extremely rare' in remote GP consultations but risk is higher...